Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 24-Nov-23 1:39 PM View:  | Baker Bros Advisors LLC 10% Owner | Bellicum Pharmaceuticals, Inc (BLCM) | 22-Nov-23 | Exercise (in-the money or at-the-money) | 2,116,350 | $0.00 | $211.63 | 850% 249.12K to 2.37M | |
| 05-Jan-23 1:12 PM View: | Daly James M Director | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-23 | Option Exercise | 60,414 | -- | -- | 122% 49.46K to 109.87K | |
| 05-Jan-23 1:04 PM View: | Klimovsky Judith V Director | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-23 | Option Exercise | 60,414 | -- | -- | 122% 49.68K to 110.1K | |
| 05-Jan-23 1:12 PM View: | Huber Reid M Director | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-23 | Option Exercise | 87,196 | -- | -- | 132% 65.98K to 153.18K | |
| 05-Jan-23 1:12 PM View: | Davis Stephen Director | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-23 | Option Exercise | 74,739 | -- | -- | 120% 62.12K to 136.85K | |
| 05-Jan-23 1:11 PM View: | Stonehouse Jon P Director | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-23 | Option Exercise | 121,452 | -- | -- | 147% 82.63K to 204.09K | |
| 02-Sep-22 10:26 AM View: | Stonehouse Jon P Director | Bellicum Pharmaceuticals, Inc (BLCM) | 01-Sep-22 | Option Exercise | 60,580 | -- | -- | 141% 43.11K to 103.69K | |
| 02-Sep-22 10:30 AM View: | Daly James M Director | Bellicum Pharmaceuticals, Inc (BLCM) | 01-Sep-22 | Option Exercise | 35,082 | -- | -- | 244% 14.38K to 49.46K | |
| 02-Sep-22 10:30 AM View: | Klimovsky Judith V Director | Bellicum Pharmaceuticals, Inc (BLCM) | 01-Sep-22 | Option Exercise | 35,082 | -- | -- | 240% 14.6K to 49.68K | |
| 02-Sep-22 10:29 AM View: | Huber Reid M Director | Bellicum Pharmaceuticals, Inc (BLCM) | 01-Sep-22 | Option Exercise | 46,489 | -- | -- | 238% 19.49K to 65.98K | |
| 02-Sep-22 10:30 AM View: | Davis Stephen Director | Bellicum Pharmaceuticals, Inc (BLCM) | 01-Sep-22 | Option Exercise | 43,400 | -- | -- | 232% 18.71K to 62.12K | |
| 06-Jan-22 9:49 AM View: | Brown James F Director | Bellicum Pharmaceuticals, Inc (BLCM) | 04-Jan-22 | Option Exercise | 28,384 | -- | -- | 100% 0 to 28.38K | |
| 06-Jan-22 9:40 AM View: | Stonehouse Jon P Director | Bellicum Pharmaceuticals, Inc (BLCM) | 04-Jan-22 | Option Exercise | 21,504 | -- | -- | 2150% 1.0K to 22.5K | |
| 06-Jan-22 9:39 AM View: | Daly James M Director | Bellicum Pharmaceuticals, Inc (BLCM) | 04-Jan-22 | Option Exercise | 14,377 | -- | -- | 100% 0 to 14.38K | |
| 06-Jan-22 9:34 AM View: | Klimovsky Judith V Director | Bellicum Pharmaceuticals, Inc (BLCM) | 04-Jan-22 | Option Exercise | 14,602 | -- | -- | 100% 0 to 14.6K | |
| 06-Jan-22 9:51 AM View: | Huber Reid M Director | Bellicum Pharmaceuticals, Inc (BLCM) | 04-Jan-22 | Option Exercise | 19,494 | -- | -- | 100% 0 to 19.49K | |
| 06-Jan-22 9:31 AM View: | Davis Stephen Director | Bellicum Pharmaceuticals, Inc (BLCM) | 04-Jan-22 | Option Exercise | 18,715 | -- | -- | 100% 0 to 18.71K | |
| 02-Jun-20 12:25 PM View: | Ward Shane Sr VP and Chief Legal SO | Bellicum Pharmaceuticals, Inc (BLCM) | 29-May-20 | Payment of Exercise | 107 | $7.63 | $816.41 | (5%) 1.99K to 1.88K | 53% |
| 19-Mar-20 12:48 PM View: | Fair Richard A. President and CEO Director | Bellicum Pharmaceuticals, Inc (BLCM) | 17-Mar-20 | Market Purchase | 5,000 | $4.00 | $19,998.50 | 73% 6.81K to 11.81K | (10%) |
| 06-Jan-20 4:29 PM View: | Foster Aaron E. Sr VP, Head of Research | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-20 | Option Exercise | 625 | -- | -- | 9% 6.89K to 7.52K | |
| 06-Jan-20 5:00 PM View: | Smith Alan K. EVP, Technical Operations | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-20 | Option Exercise | 1,563 | -- | -- | 26% 5.98K to 7.54K | |
| 06-Jan-20 5:15 PM View: | Williams Rosemary Y. VP, Finance & PAO | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-20 | Option Exercise | 781 | -- | -- | 15% 5.27K to 6.05K | |
| 06-Jan-20 5:00 PM View: | Smith Alan K. EVP, Technical Operations | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-20 | Payment of Exercise | 589 | $1.40 | $824.60 | (8%) 7.54K to 6.96K | 74% |
| 06-Jan-20 4:29 PM View: | Foster Aaron E. Sr VP, Head of Research | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-20 | Payment of Exercise | 236 | $1.40 | $330.40 | (3%) 7.52K to 7.28K | 74% |
| 06-Jan-20 5:15 PM View: | Williams Rosemary Y. VP, Finance & PAO | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-20 | Payment of Exercise | 295 | $1.40 | $413.00 | (5%) 6.05K to 5.76K | 74% |
| 06-Jan-20 5:00 PM View: | Smith Alan K. EVP, Technical Operations | Bellicum Pharmaceuticals, Inc (BLCM) | 02-Jan-20 | Payment of Exercise | 883 | $1.51 | $1,333.33 | (13%) 6.87K to 5.98K | 76% |
| 06-Jan-20 4:29 PM View: | Foster Aaron E. Sr VP, Head of Research | Bellicum Pharmaceuticals, Inc (BLCM) | 02-Jan-20 | Payment of Exercise | 942 | $1.51 | $1,422.42 | (12%) 7.83K to 6.89K | 76% |
| 06-Jan-20 5:15 PM View: | Williams Rosemary Y. VP, Finance & PAO | Bellicum Pharmaceuticals, Inc (BLCM) | 02-Jan-20 | Payment of Exercise | 483 | $1.51 | $729.33 | (8%) 5.75K to 5.27K | 76% |
| 06-Jan-20 4:29 PM View: | Foster Aaron E. Sr VP, Head of Research | Bellicum Pharmaceuticals, Inc (BLCM) | 02-Jan-20 | Option Exercise | 2,500 | -- | -- | 47% 5.33K to 7.83K | |
| 06-Jan-20 5:00 PM View: | Smith Alan K. EVP, Technical Operations | Bellicum Pharmaceuticals, Inc (BLCM) | 02-Jan-20 | Option Exercise | 2,344 | -- | -- | 52% 4.52K to 6.87K | |
| 06-Jan-20 5:15 PM View: | Williams Rosemary Y. VP, Finance & PAO | Bellicum Pharmaceuticals, Inc (BLCM) | 02-Jan-20 | Option Exercise | 1,282 | -- | -- | 29% 4.47K to 5.75K | |
| 14-Nov-19 5:11 PM View: | Woodard Jr Joseph Paul SVP Clinical & Medical Affairs | Bellicum Pharmaceuticals, Inc (BLCM) | 13-Nov-19 | Payment of Exercise | 1,597 | $0.82 | $1,309.54 | (23%) 7.06K to 5.47K | 56% |
| 14-Nov-19 5:11 PM View: | Woodard Jr Joseph Paul SVP Clinical & Medical Affairs | Bellicum Pharmaceuticals, Inc (BLCM) | 13-Nov-19 | Option Exercise | 3,750 | -- | -- | 113% 3.31K to 7.06K | |
| 11-Sep-19 7:01 PM View: | Fair Richard A. President and CEO Director | Bellicum Pharmaceuticals, Inc (BLCM) | 10-Sep-19 | Market Purchase | 40,000 | $1.25 | $50,000.00 | 151% 26.56K to 66.56K | (71%) |
| 30-Aug-19 4:01 PM View: | Ward Shane Sr. VP and General Counsel | Bellicum Pharmaceuticals, Inc (BLCM) | 29-Aug-19 | Market Purchase | 8,000 | $1.23 | $9,821.60 | 78% 10.29K to 18.29K | (71%) |
| 23-Aug-19 4:03 PM View: | Fair Richard A. President and CEO Director | Bellicum Pharmaceuticals, Inc (BLCM) | 21-Aug-19 | Market Purchase | 20,000 | $0.99 | $19,780.00 | 305% 6.56K to 26.56K | (63%) |
| 23-Aug-19 4:04 PM View: | Naeve Gregory S. Chief Business Officer | Bellicum Pharmaceuticals, Inc (BLCM) | 21-Aug-19 | Payment of Exercise | 1,597 | $0.95 | $1,513.48 | (10%) 15.34K to 13.75K | 62% |
| 30-May-19 4:05 PM View: | Ward Shane Sr. VP and General Counsel | Bellicum Pharmaceuticals, Inc (BLCM) | 29-May-19 | Payment of Exercise | 1,065 | $2.09 | $2,225.85 | (11%) 10.0K to 8.94K | 83% |
| 07-Feb-19 4:02 PM View: | Grossman William Sr. VP, Chief Medical Officer | Bellicum Pharmaceuticals, Inc (BLCM) | 05-Feb-19 | Payment of Exercise | 3,126 | $3.48 | $10,878.50 | (10%) 30.0K to 26.87K | 90% |
| 04-Jan-19 4:02 PM View: | Spencer David M. Chief Technology Officer | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-19 | Payment of Exercise | 589 | $3.20 | $1,884.80 | (< 1%) 93.06K to 92.47K | 89% |
| 04-Jan-19 4:03 PM View: | Williams Rosemary Y. Principal Accounting Officer | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-19 | Payment of Exercise | 295 | $3.20 | $944.00 | (6%) 4.77K to 4.47K | 89% |
| 04-Jan-19 4:01 PM View: | Smith Alan K. EVP, Technical Operations | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-19 | Option Exercise | 1,562 | -- | -- | 44% 3.55K to 5.11K | |
| 04-Jan-19 4:02 PM View: | Spencer David M. Chief Technology Officer | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-19 | Option Exercise | 1,562 | -- | -- | 2% 91.5K to 93.06K | |
| 04-Jan-19 4:01 PM View: | Smith Alan K. EVP, Technical Operations | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-19 | Payment of Exercise | 589 | $3.20 | $1,884.80 | (12%) 5.11K to 4.52K | 89% |
| 04-Jan-19 4:03 PM View: | Williams Rosemary Y. Principal Accounting Officer | Bellicum Pharmaceuticals, Inc (BLCM) | 03-Jan-19 | Option Exercise | 782 | -- | -- | 20% 3.98K to 4.77K | |
| 04-Jan-19 4:01 PM View: | Smith Alan K. EVP, Technical Operations | Bellicum Pharmaceuticals, Inc (BLCM) | 02-Jan-19 | Option Exercise | 2,344 | -- | -- | 112% 2.09K to 4.43K | |
| 04-Jan-19 4:03 PM View: | Naeve Gregory S. Chief Business Officer | Bellicum Pharmaceuticals, Inc (BLCM) | 02-Jan-19 | Option Exercise | 2,031 | -- | -- | 15% 13.4K to 15.43K | |
| 04-Jan-19 4:02 PM View: | Spencer David M. Chief Technology Officer | Bellicum Pharmaceuticals, Inc (BLCM) | 02-Jan-19 | Option Exercise | 2,500 | -- | -- | 3% 89.94K to 92.44K | |
| 04-Jan-19 4:01 PM View: | Smith Alan K. EVP, Technical Operations | Bellicum Pharmaceuticals, Inc (BLCM) | 02-Jan-19 | Payment of Exercise | 883 | $3.33 | $2,940.39 | (20%) 4.43K to 3.55K | 89% |
| 04-Jan-19 4:03 PM View: | Williams Rosemary Y. Principal Accounting Officer | Bellicum Pharmaceuticals, Inc (BLCM) | 02-Jan-19 | Option Exercise | 1,281 | -- | -- | 40% 3.19K to 4.47K |
